Journal of Clinical Pediatrics >
Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen
Received date: 2023-09-12
Online published: 2024-08-06
Objective To explore the efficacy and safety of different doses of cytarabine (Ara-C) in FLAG-IDA regimen as induction therapy in children with acute myeloid leukemia (AML). Methods 121 children who newly diagnosed AML from January 2015 to October 2022 were enrolled in this study. Participants were divided into two groups according to the dose of cytarabine used in the FLAG-IDA induction chemotherapy regimen: the standard-dose (SD) group and the high-dose (HD) group. Therapeutic efficacy and toxicity and side effects of the two groups after the induction chemotherapy were compared. Result A total of 121 children with AML were included, 71 males and 50 females, with a median age at first diagnosis of 6.7 (2.6~10.9) years. There were 30 cases in the SD group and 91 cases in the HD group. Compared with the SD group, the CR rate of induction chemotherapy in the HD group was lower, the duration of neutropenia was shorter, and the levels of AST and ALT after chemotherapy were higher, and the difference was statistically significant (P<0.05). There was no statistically significant difference in toxic and side effects between the two groups (P>0.05). The median follow-up time was 37.0 (12.0~46.0) months. The 3-year OS and EFS of the SD group were (91.1±6.0) % and (79.5±8.3) % respectively, and the 3-year OS and EFS of the HD group were (64.5±11.5) %and (57.5±10.7) % respectively. There was no statistically significant difference in 3-year OS and EFS between the two groups (P>0.05). Conclusion Standard-dose cytarabine can obtain better efficacy and less side effects in induction chemotherapy.
Key words： acute myeloid leukemia; cytarabine; efficacy; child
Yirong LI , Huiping LI , Jingyu GAO , Yuhua XIAO , Xiaomin CHEN , Yanling LU , Nana ZHAO , Xiaoqin FENG . Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen[J]. Journal of Clinical Pediatrics, 2024 , 42(8) : 673 -677 . DOI: 10.12372/jcp.2024.23e0900
| [1] | Ganzel C, Manola J, Douer D, et al. Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN cancer research group trials, 1980-2008[J]. J Clin Oncol, 2016, 34(29): 3544-3553. |
| [2] | Russell N, Hills R, Kjeldsen L, et al. Treatment inten-sification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial[J]. Br J Haematol, 2022, 196(6): 1344-1347. |
| [3] | Doval D, Kumar Sharma S, Kumar M, et al. Cytarabine ears - A side effect of cytarabine therapy[J]. J Oncol Pharm Pract, 2020, 26(2): 471-473. |
| [4] | Chanswangphuwana C, Polprasert C, Owattanapanich W, et al. Comparison of three doses of cytarabine consolidation for intermediate- and adverse-risk acute myeloid leukemia: real world evidence from Thai acute myeloid leukemia registry[J]. Clin Lymphoma Myeloma Leuk, 2022, 22(10): e915-e921. |
| [5] | Schaich M, Parmentier S, Kramer M, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial[J]. J Clin Oncol, 2013, 31(17): 2094-2102. |
| [6] | Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. |
| [7] | D?hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022, 140(12): 1345-1377. |
| [8] | Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel[J]. Blood, 2012, 120(16): 3187-3205. |
| [9] | Schneider C, Oellerich T, Baldauf HM, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia[J]. Nat Med, 2017, 23(2): 250-255. |
| [10] | 陈冬, 陆滢, 裴仁治, 等. 地西他滨联合低剂量阿糖胞苷治疗老年复发/难治性急性髓系白血病患者的疗效、预后及安全性分析[J]. 中国实验血液学杂志, 2019, 27(2): 390-395. |
| [11] | 任欣, 赵婷, 王婧, 等. 去甲氧柔红霉素联合阿糖胞苷治疗初发急性髓系白血病的预后分析[J]. 中华血液学杂志, 2018, 39(1): 15-21. |
| [12] | Borthakur G, Ravandi F, Patel K, et al. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gem-tuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients[J]. Am J Hematol, 2022, 97(11): 1427-1434. |
| [13] | 曹欣欣, 王书杰, 段明辉, 等. 大剂量阿糖胞苷巩固治疗初治急性髓系白血病患者的疗效和安全性分析[J]. 中华血液学杂志, 2017, 38(4): 330-333. |
| [14] | Kadia TM, Cortes J, Ravandi F, et al. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial[J]. Lancet Haematol, 2018, 5(9): e411-e421. |
| [15] | 杨辉, 于新发, 董维. 氟达拉滨联合中剂量阿糖胞苷用于急性髓系白血病巩固治疗的疗效[J]. 实用医学杂志, 2016, 32(15): 2547-2549. |
| [16] | D?hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. |
| [17] | Li W, Gong X, Sun M, et al. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis[J]. PLoS One, 2014, 9(10): e110153. |
| [18] | Yang F, Anekpuritanang T, Press RD. Clinical utility of next-generation sequencing in acute myeloid leukemia[J]. Mol Diagn Ther, 2020, 24(1): 1-13. |
| [19] | DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia[J]. Am J Hematol, 2022, 97(8): 1035-1043. |
| [20] | 黄达永, 魏娜, 付丽, 等. 阿糖胞苷分别联合柔红霉素和去甲氧柔红霉素诱导治疗初治急性髓系白血病临床效果比较[J]. 白血病·淋巴瘤, 2016, 25(10): 592-594. |
/
| 〈 |
|
〉 |
